BENEDUSI ANNA (IT)
GIULIANI GIAMMARIA (IT)
BENEDUSI ANNA (IT)
| US20050175555A1 | 2005-08-11 | |||
| EP1328268B1 | 2005-03-23 | |||
| US20050175555A1 | 2005-08-11 |
MUKHERJEE, SUBHENDU ET AL.: "Cardioprotection with the Parrodiene 2,4,6- Octatrienal and Its Potassium Salt through Activation of the Akt-Bcl-2 Survival Pathway", JOURNAL OF NATURAL PRODUCTS, vol. 72, no. 5, pages 871 - 875, XP002599834, DOI: doi:10.1021/NP800444A
| CLAIMS 1 . Use of compounds of general formula (I): CH3 (-CH=CH)3-R (I) wherein R is selected from CO-O-R' or CO-O(_), R' being selected from H, alkyl or alkenyl from Ci to C22, or sugars, and their pharmaceutically acceptable salts, preferably such as sodium, potassium or lysine salts each compound of general formula (I) being used as such or in a mixture with one or more of the others, as active ingredients in a pharmaceutical or cosmetic composition provided with antioxidant activity against free radicals. 2. The use according to claim 1 to combat the oxidizing action of free radicals and preserve the physiological conditions of the human epidermis. 3. The use according to claim 1 to combat the oxidizing action of free radicals on the human scalp and preserve the physiological conditions of hair. 4. Use of compounds of general formula (I): CH3 (-CH=CH)3-R (I) wherein R is selected from CO-O-R' or CO-O^, R' being selected from H, alkyl or alkenyl from Ci to C22, or sugars, and their pharmaceutically acceptable salts, preferably such as sodium, potassium or lysine salts each compound of general formula (I) being used as such or in a mixture with one or more of the others, for the preparation of a pharmaceutical or cosmetic composition provided with antioxidant activity against free radicals. 5. A composition for a use according to any one of the preceding claims, wherein said active ingredient is a compound of general formula (I) used as such or in a mixture with one or more of the other compounds. 6. The composition according to claim 5, wherein said active ingredient is 2,4,6- octatrienoic acid. 7. The composition according to claim 5, wherein said active ingredient is a salt of 2,4,6-octatrienoic acid. 8. The composition according to claim 7, wherein said active ingredient is the sodium salt of 2,4,6-octatrienoic acid. 9. The composition according to claim 7, wherein said active ingredient is the potassium salt of 2,4,6-octatrienoic acid. 10. The composition according to claim 7, wherein said active ingredient is the L- Lysine salt of 2,4,6-octatrienoic acid. 11. The composition according to claim 5, wherein said active ingredient is the ethyl ester of 2,4,6-octatrienoic acid. 12. The composition according to claim 5, wherein said active ingredient is a mixture of two or more of the compounds of formula (I). 13. The composition according to any one of the preceding claims comprising said active ingredient in a quantity ranging from 0.0003 to 0.0036 mol/100g. 14. The composition according to any one of the preceding claims comprising said active ingredient formulated with suitable excipients for topical application to the human skin or scalp. |
FIELD OF THE INVENTION
The present invention relates to compounds provided with antioxidant activity against free radicals, for use as active ingredients for preparation of pharmaceutical or cosmetic compositions.
PRIOR ART
Antioxidant activity against free radicals has been and is the object of numerous studies both in the pharmaceutical field and in the cosmetic field. For example, EP1328268 B1 of the same applicant relates to a composition provided with said kind of activity produced by certain flavonoids extracted from red wine, in particular a combination of quercetin and catechin active ingredients formulated for oral use, which can be used in various applications in the pharmaceutical or nutritional or cosmetic field essentially based on said antioxidant activity against free radicals. DESCRIPTION OF THE INVENTION
According to the present invention, it has now been found, surprisingly, that a remarkable antioxidant activity against free radicals is generated by compounds of general formula (I):
CH 3 (-CH=CH) 3 -R (I) wherein R is selected from CO-O-R' or CO-O ( ) , R' being selected from H, alkyl or alkenyl from Ci to C22, or sugars, and their pharmaceutically acceptable salts, preferably such as sodium, potassium, or lysine salts.
An experimental study, reported hereunder in the present description, in fact showed that surprisingly for said compounds of the invention it is possible to obtain significant antioxidant activity against free radicals.
The invention also relates to pharmaceutical and cosmetic compositions derived therefrom, each compound of general formula (I) being used in said compositions as such or mixed with the others. The invention therefore relates to the use of the compounds of formula (I) as active ingredients for any therapeutic or cosmetic application in which said antioxidant activity against free radicals produces an advantageous effect. In particular this relates to applications on the human skin and scalp to combat the oxidant action of free radicals and preserve the physiological conditions of the epidermis and of the hair subjected to said action.
Characterizing data and formulae of some of the preferred compounds of general formula (I) are given below, with reference to octatrienoic acid and its salts or esters:
C 8 H 10 O 2 MW 138.17
2E,4E,6E-Octa-2,4,6-trienoic acid
CAS #: 5205-32-3
2E,4E,6E-Octa-2,4,6-trienoic acid potassium salt
CAS #: 1147842-10-1
C 8 H 9 O 2 Na MW 160.15
2E,4E,6E-Octa-2,4,6-trienoic acid sodium
CAS #: not available
C 8 H902-C6Hi5N 2 O2 MW 284.36
2E,4E,6E-Octa-2,4,6-trienoic acid L-lysine
CAS #: not available
CioH 14 0 2 MW 166.22
2E,4E ) 6E-Octa-2,4,6-trienoic acid ethyl ester
CAS #5941-49-1
A composition of the invention is preferably formulated for topical administration on the skin or on the scalp, and comprises said active ingredient in a quantity ranging from 0.0003 to 0.0036 mol/100g.
This range corresponds to a range from 0.04 to 0.6 wt.% of the composition for octatrienoic acid, or for the corresponding sodium or potassium salt or for the corresponding ethyl ester, whereas it corresponds to a range from 0.11 to 1.4 wt.% of the composition in the case of the corresponding lysine salt.
Examples are given below - not intended to be in any way limiting - of compositions suitable in particular for the cosmetic use specified herein.
The quantities of the components, identified according to the INCI nomenclature, are expressed as percentages by weight varying over the stated ranges:
- -Example 1 - - - - ■ ·
SHAMPOO
Component (INCI name) Quantity w/w (%)
Disodium Laureth Sulphosuccinate 1.00-5.00
Magnesium Laureth Sulphate 5.00-9.00
PEG-7 Glyceryl Cocoate 0.50-1.00
Cocamide MIPA 0.50-2.00 PEG-200 Hydrogenated Glyceryl Palmate 0.50-2.00
Polyquatemium-10 0.10-0.50
Tetrasodium EDTA 0.05-0.20
Sodium Lauroyl Sarcosinate 1.00-4.00
Tetrasodium EDTA 0.05-0.20
Sodium octatrienoate 0.048-0.6
BHA 0.005-0.015
Potassium Undecylenoyl Wheat Protein 0.50-1.00
Phenyl Trimethicone 0.5- .50
Silicone Quaternium-15 0.01-0.07
Laureth-4 0.01-0.80
Perfume 0.10-0.80
Glycol Distearate 0.50-1.00
Laureth-7 0.50-0.80
Sodium Cocoamphoacetate 0.05-3.00
Cocamidopropyl Betaine 0.01-2.00
Sodium Laureth Sulphate 0.01-3.00
Sodium Hydroxymethylglycinate 0.20-0.45
Benzoic acid 0.005-0.10
Citric acid q.s.
Aqua q.s. 100.00
Example 2
MEDIUM-PROTECTION SUN PROTECTION
Component (INCI name) Quantity w/w (%)
Aqua 40.00-60.00
C12-15 alkyl benzoate. .5.00-7.00
Ethylhexyl methoxycinnamate 3.00-7.00
Isostearyl isostearate 2.00-8.00
Styrene/Acrylates Copolymer .00-5.00
Acrylates/C 10-30 Alkyl Acrylate Crosspolymer 0.05-0.70
Butylene glycol cocoate 1.00-5.00
Butyl methoxydibenzoylmethane 1.00-5.00 Diethylamino HydroxybenzoyI Hexyl Benzoate 1.00-5.00
Ethylhexyl Triazone 1.00-5.00
Octocrylene 1.00-5.00
Polyurethane - 34 1.00-5.00
PPG-15 stearyl ether 1.00-5.00
Diethylhexyl syringylidene malonate 0.10-1.00
Sorbityl furfural 0.05-0.10
Octatrienoic acid 0.04-0.5
Quercetin 0.001-0.005
Ethylhexylglycerin 0.15-0.60
Coleus forskohlii root extract 0.005-0.50
Polyperfluoroethoxymethoxy Difluoroethyl PEG Phosphate...0.2-1.50
Perfume 0.1-0.5
Phenoxyethanol 0.80-1.00
Sodium Hydroxide q.s.
Example 3
LOTION AGAINST HAIR LOSS
Component (I NCI name) Quantity w/w (%)
Alcohol denat 10.00-30.00
Disodium EDTA 0.025-0.20
Octatrienoic acid 0.04-0.5
Biotin 0.001-0.005
Perfume 0.30
Ajuga reptans leaf extract 0.01-0.05
Calcium pantothenate 0.05-0.40
PEG-40 Hydrogenated Castor Oil 0.20-1.00
Aqua q.s. 100.00 Example 4
AFTER-SUN BODY MILK
Component (INCI name) Quantity w/w (%)
Glycerin 1.00-6.00
Methylpropanediol .00-6.00
Cetyl hydroxyethylcellulose 0.10-0.40
Xanthan gum 0.10-0.40
Tapioca starch 1 -00-2.00
Disodium EDTA 0.025-0.20
Octatrienoic acid 0.04-0.5
Sorbitan stearate 2.00-5.00
Sucrose cocoate 0.10-1.00
Ethylhexyl palmitate 1.00-5.00
Hydrogenated polydecene 100-5.00
Caprylic/capric triglycerides .00-5.00
Butyrospermum parkii 1.00-5.00
Meadowfoam (Limnanthes alba) seed oil 1.00-3.00
Dimethicone · 1.00-3.00
Sodium hydroxymethylglycinate 0-10-0.20
Phenoxyethanol 0.70-0.90
Lactic acid °. s -
Perfume 0· 30
Delta tocopherol 0.02-0.25
Sorbityl furfural 0.10-0.90
Aqua q-s. 100.00
Example 5
FACE CREAM
Component (INCI name) Quantity w/w (%)
Glycerin 2.00-5.00
Diglycerin 0.20-2.00
Cetearyl alcohol 0.20-2.50 Cetearyl glucoside 0.20-2.50
PEG-100 Stearate <- 0.20-1.00
Sorbityl furfural 0.5-1.00
Tetrasodium Glutamate Diacetate 0.10-0.50
Octatrienoic acid 0.04-0.5
Palm butter 0.50-3.00
Hydrogenated Evening Primrose Oil 0.50-3.00
Octyldodecanol 0.50-3.00
Hydrogenated castor oil 1.00-4.00
Ethylhexyl cocoate 1.00-4.00
Acrylates/C10-30 AlkyI acrylate crosspolymer 1.00-2.00
Butyrospermum parkii .00-5.00
Beta sitosterol 0.10-0.50
Delta tocopherol 0.05-0.20
Dimethicone 0.50-1.50
Dimethicone crosspolymer 0.10-1.50
Ethylhexylglycerin 0.25-0.50
Phenoxyethanol ■■■■ 0.50-0.99
Perfume q s.
Aqua q s. 100.00
Example 6
LEAVE-ON MAKE-UP REMOVER
Component (INCI name) Quantity w/w (%)
Glycerin 2.00-5.00
Ethylhexylglycerin 0.25-0.50
Potassium octatrienoate 0.05-0.6 "
Trehalose 0.50-1.00
PPG-26 Buteth-26 2.00-15.00
PEG-40 Hydrogenated Castor Oil 2.00-15.00
Methylpropanediol 1.00-6.00
Aqua 60.00-80.00 DESCRIPTION OF THE DRAWINGS
Figs. 1 and 2 of the appended drawings show graphs taken from an experimental study as described hereunder.
Experimental study: in-vitro evaluation of the antioxidant effects of the compounds of the invention
The purpose of the study was to evaluate in vitro the modulation of the production of ROS (reactive oxygen species), according to Fig. 1 , and lipid lipoperoxidation, according to Fig. 2, by the following compounds of the invention:
compound 1 : 2E,4E,6E-octatrienoic acid
compound 2: potassium 2E,4E,6E-octatrienoate
compound 3: 2E,4E,6E-octatrienoic acid, L-lysine salt,
compared with a control.
Experimental models
Two cellular systems were used: NCTC 2544, a line of human keratinocytes, and THP-1 , a human promyelocytic line. The results were expressed as mean ± standard deviation. Each experiment was repeated at least twice.
Parameters evaluated and results obtained
a) Modulation of the production of ROS
Tributyltin (TBT) and lipopolysaccharide (LPS) are used as endogenous inducers of radical species. The production of ROS was evaluated by cytofluorometry techniques for the THP-1 cell line, using DCFH as stain.
The optimum times and concentrations for cytofluorometric measurement of ROS were identified in preliminary experiments.
The vitamin E derivative 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), at a concentration of 100 μΜ, was used as positive control.
The results obtained are shown in the graph in Fig. 1.
The THP-1 cells were treated for 1 hour with compounds 1 and 2 of the invention at a concentration of 100 μg/ml, with compound 3 at a concentration of 200 μg/ml and with Trolox 100 μΜ in serum-free medium, loaded in the last 30 minutes with DCFH (10 μΜ) and then treated in the presence or absence of LPS (0.1 μg ml) and analysed in the cytofluorometer. As can be seen from the graph, the compounds of the invention proved to be capable of nullifying the production of ROS induced by LPS 0.1 μg/ml to an extent not less than Trolox.
b) Lipid lipoperoxidation
Lipid peroxidation was evaluated on the NCTC 2544 cells by measuring the content of malondialdehyde, one of the main by-products of lipid peroxidation, through its reactivity with thiobarbituric acid. The results are expressed as absorbance/mg protein. The protein content was evaluated by the Bradford method.
The NCTC cells were treated for 24 hours in the presence or in the absence of the maximum tolerated concentration of said compounds 1 , 2, 3, and then stimulated with TBT 1-2.5 μΜ for a further 24 hours.
Trolox 100 μΜ was used as positive control.
The results obtained are presented in the graph in Fig. 2.
As can be seen, for the cells treated with said compounds 1 , 2, 3, a statistically significant (p<0.05) decrease of lipoperoxidation induced by TBT 2.5 μΜ was observed at 24 hours, confirming the effect of the invention.